Your web browser doesn’t have the Flash Player v.18 plugin installed, so this Website can’t be properly viewed.
For full experience, please download the latest Flash plugin at Adobe.com.
Download Adobe Flash Player now.

GARDASIL®

Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine


Diseases THAT CAN BE CAUSED BY HUMAN PAPILLOMAVIRUS

Human papillomavirus: 1 Virus, More Than 1 Disease

Some genital HPV types are known as "high risk" because they can cause cervical cancerCervical cancerCervical cancer is cancer of the cervix, the lower part of the uterus that connects to the vagina. It can be a result of certain high risk types of HPV.
See Full Glossary
,
vaginal cancerVaginal cancerA disease in which cancer cells form in the vagina (tube from vulva to cervix).
See Full Glossary
, and vulvar cancerVulvar cancerCancer in which the tumour is in the vulva (outer part of vagina).
See Full Glossary
(in women), and anal cancerAnal cancerHPV infection is strongly associated with anal cancer and the precancerous anal lesions that precede cancer. Most anal cancers are squamous cell carcinoma and 80-90% of these cancers are HPV positive. HPV types 16 and 18 are the most commonly associated types.)
See Full Glossary
(in men and women). Although HPV types 16 and 18 are not the only high risk types, these two types do cause over 70% of cervical cancers.*

Other genital HPV types are known as “low risk”, but this does not mean no risk. They can cause health problems like genital warts (skin-coloured growths that may hurt, itch and bleed) in men and women. HPV types 6 and 11 cause over 90% of genital warts.

HPV is also a major cause of abnormal Pap tests.

Get the facts about these diseases now.

* GARDASIL® does not provide protection against all high risk types of HPV.

Talk to your healthcare professional if you want to know more about the diseases that can be caused by human papillomavirus.


IMPORTANT INFORMATION ABOUT GARDASIL®

In girls and women ages 9 to 45, GARDASIL® helps prevent infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: cervical, vaginal, and vulvar cancers caused by HPV types 16 and 18; abnormal and precancerous vaginal and vulvar lesions, abnormal and precancerous cervical lesions as found in Pap tests, caused by types 6, 11, 16 and 18; and genital warts caused by types 6 and 11.

In girls and women ages 9 to 26, GARDASIL® also helps protect against anal cancer caused by HPV types 16 and 18, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.

In boys and men ages 9 to 26, GARDASIL® helps protect against infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: anal cancer caused by HPV types 16 and 18, genital warts caused by types 6 and 11, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.

GARDASIL® helps prevent these diseases, but it does not treat them. And just like all vaccines, GARDASIL® may not fully protect everyone who gets it. GARDASIL® does not protect against all types of HPV. Duration of protection continues to be studied. GARDASIL® does not protect against other sexually transmitted infections.

Even if vaccinated with GARDASIL®, it is still important for women to continue having regular Pap tests. Recipients of GARDASIL® should not discontinue anal cancer screening if it has been recommended by a healthcare provider. Vaccination with GARDASIL® is not recommended during pregnancy.

Like all vaccines, GARDASIL® may cause some side effects. GARDASIL® has been shown to be generally well tolerated in adults and children as young as age 9. The most commonly reported side effects included pain, swelling, itching, bruising and redness where the shot was given, fever, nausea, dizziness, headache, vomiting and pain in extremity.

Fainting has been reported. Fainting can occur after vaccination, most commonly among adolescents and young adults. Although fainting episodes are uncommon, vaccinees should be observed for 15 minutes after they receive GARDASIL®.

Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives, and rash have been reported.

These were not all the side effects reported. If you notice any unusual or severe symptoms after receiving GARDASIL®, contact your healthcare professional as soon as possible.

Information about GARDASIL® is provided in the Consumer Information. To retrieve this information you will be re-directed to a page within our main Merck Website, which contains the Consumer Information.

Click here to go to the Gardasil® Consumer Information.

To view PDF documents, you must have Adobe Acrobat Reader®

To view PDF documents, you must have Adobe Acrobat Reader® By clicking on this link, you will be leaving this site This link will take you to a site outside of Merck Canada Inc.

Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
Proceed
installed on your computer.







This site is intended only for residents of Canada. This Website is for information purposes only.
® Merck Sharp & Dohme Corp. Used under license.

© 2016 Merck Canada Inc. All rights reserved.
VACC-1158121-0000 FE 2017